|
|
|
Feed Submission If you'd like OHCNetwork Health News to link to your health news or blog from this category (Huntingtons Disease - Neurological Disorders - Diseases and Conditions), please submit your RSS or XML feed to OHCNetwork Health News. Contact information is available here. |
Health News >> Diseases and Conditions >> Neurological Disorders >> Huntingtons Disease
Huntingtons Disease News
Huntingtons Disease News From Medical News Today
Cambridge Laboratories Group Limited ("Cambridge"), the privately-owned specialty pharmaceutical company, today announces that XENAZINE(R) (tetrabenazine), the first and only product approved for the treatment of chorea associated with Huntington's disease, has been launched in the US.
Huntingtons Disease News From Medical News Today
Defective calcium metabolism in nerve cells may play a major role in a fatal genetic neurological disorder that resembles Huntington's disease, researchers at UT Southwestern Medical Center have found in a mouse study. The disease, called spinocerebellar ataxia 3 - also known as SCA3, or Machado-Joseph disease - is a genetic disorder that, like Huntington's, impairs coordination, speech, and vision and causes brain atrophy.
Huntingtons Disease News From Medical News Today
OVATION Pharmaceuticals, Inc. announced today that Xenazine* (tetrabenazine) Tablets, an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease (HD), is now available throughout the United States. Xenazine is the first and only FDA-approved treatment specifically developed for any HD-related symptom.
Huntingtons Disease News From Medical News Today
"Huntington's disease presents an ideal vantage point to study neurodegenerative disease, because we know the misfolded protein that's responsible," says Martin Duennwald, formerly a postdoctoral researcher in the lab of Whitehead Member Susan Lindquist. "But we don't understand how this protein causes cellular damage and death for the neurons that are affected.
Huntingtons Disease News From Medical News Today
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's").
Huntingtons Disease News From Medical News Today
Columbia University will award the 2008 Louisa Gross Horwitz Prize to F. Ulrich Hartl, M.D., professor and director of the Department of Cellular Biochemistry at the Max Planck Institute of Biochemistry in Germany, and Arthur Horwich, M.D.
Huntingtons Disease News From Medical News Today
Therapeutic strategies to strengthen antioxidant defences could help to prevent the progression of Huntington's Disease. This is the suggestion from the results of the first ever trial on human samples carried out by researchers at the University of Lleida. The results have been published in the latest issue of Free Radical Biology & Medicine magazine.
Huntingtons Disease News From Medical News Today
Findings establish a platform to understand G protein-coupled receptors; may help in development of new class of Parkinson's treatments Scientists from The Scripps Research Institute have determined the structure of an adenosine receptor that plays a critical role in a number of important physiological processes including pain, breathing, and heart function.
Huntingtons Disease News From Medical News Today
Duke University Medical Center scientists have made a significant finding that could lead to better drugs for several degenerative diseases including Huntington's disease and Alzheimer's disease. Compounds that block the activity of a specific enzyme prevented brain injury and greatly improved survival in fruit flies that had the same disease process found in Huntington's disease.
Huntingtons Disease News From Medical News Today
Repligen Corporation (Nasdaq: RGEN) reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease.
Huntingtons Disease News From Medical News Today
Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer's disease (http://www.connectionstudy.
Huntingtons Disease News From Medical News Today
PCP2 Shapes Light Response of ON Bipolar Cells Ying Xu, Pyroja Sulaiman, Rod Feddersen, Jian Liu, Robert G. Smith, and Noga Vardi Activation of G-protein-coupled receptors (e.g., metabotropic glutamate receptors in retinal ON bipolar cells) causes GTP to bind to the G-protein in place of GDP, resulting in dissociation and activation of Gα and Gβγ subunits and subsequent downstream effects (e.g., closing of cation channels).
Huntingtons Disease News From Medical News Today
The US Food and Drug Administration (FDA) announced on Friday that it has approved Prestwick Pharmaceuticals Inc's new drug Xenazine (generic name tetrabenazine) for the treatment of chorea in people with Huntington's disease, heralding the first treatment to receive US approval for any of the disease's symptoms. Huntington's is a rare inherited neurological disorder characterized by chorea or jerky, uncontrolled movements.
Huntingtons Disease News From Medical News Today
The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease. "Chorea is a major cause of disability and death in patients with Huntington's disease.
Huntingtons Disease News From Medical News Today
US researchers have found a way to produce immortal cell strains and tissue types from diseased patients by converting their cells into pluripotent stem cells with the same genetic errors. The new cell lines will enable scientists to investigate ten different genetic disorders like Parkinson's, muscular dystrophy, and type 1 diabetes in the test tube instead of in the patient, a huge step forward compared to current methods.
Huntingtons Disease News From Medical News Today
Huntington's disease normally only begins to cause its tell-tale memory and physical coordination impairments after affected individuals reach the age of 30. The nerve damage that creates these impairments is thought to be partly due to a destructive immune response in the brain. The current study now shows that this inflammatory response starts to brew elsewhere in the body long before it inflicts brain damage.
Huntingtons Disease News From Medical News Today
The damage to brain tissue seen in Huntington's disease may be caused by an overactive immune response in the bloodstream and the brain, according to new findings from two teams of researchers at the University of Washington in Seattle and University College London. The findings were published online July 14 in the Journal of Experimental Medicine.
Huntingtons Disease News From Medical News Today
Medivation, Inc. (NASDAQ: MDVN) announced top-line results of a Phase 2 study showing that its investigational drug Dimebon? significantly improved cognitive function in patients with mild-to-moderate Huntington's disease (HD). Cognitive function was significantly improved over placebo (p=0.03) as measured by the Mini-Mental State Examination (MMSE), the cognition scale most widely used by clinicians to assess patients with neurodegenerative diseases.
Huntingtons Disease News From Medical News Today
Medivation, Inc. (Nasdaq: MDVN) announced top-line results of a Phase 2 study showing that its investigational drug Dimebon(TM) significantly improved cognitive function in patients with mild-to-moderate Huntington's disease (HD). Cognitive function was significantly improved over placebo (p=0.03) as measured by the Mini-Mental State Examination (MMSE), the cognition scale most widely used by clinicians to assess patients with neurodegenerative diseases.
Huntingtons Disease News From Medical News Today
On June 10, 2008 the scientific journal Vaccine published a paper by the Massachusetts based biotech company Cure Lab, Inc., demonstrating that a protein sequence important in neurodegenerative Huntington's disease can be safely used as a new generation of vaccine adjuvants. The major component of every vaccine is an antigen that elicits specific immunity to a particular virus, bacteria or even cancer cells.
Huntingtons Disease News From Medical News Today
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for cysteamine bitartrate ("cysteamine") for the treatment of Huntington's disease ("HD"). Cysteamine is currently approved by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare lysosomal storage disease.
Huntingtons Disease News From Medical News Today
Kevin Harrington, a Bay Area native suffering from the effects of Huntington's Disease, may have lost his mother, grandfather, great-grandfather and a great uncle to this tragic disease but he refuses to lose hope for a cure. So he organized the 2008 Mason-McDuffie Mortgage Invitational "Swinging to Cure Huntington's Disease" golf tournament to be held at the Blackhawk Country Club on Monday, June 16th, 2008.
Huntingtons Disease News From Medical News Today
The Huntington Study Group has launched a Phase III clinical trial, funded by the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health [NIH]), to determine the effect of the maximum effective dosage of Coenzyme Q10 on cognitive function in individuals with Huntington's Disease (HD). They will also examine the long-term safety of CoQ10.
Huntingtons Disease News From Medical News Today
Scientists have created a tool for mopping up the clumps of mutant protein that drive neurodegeneration in Huntington's disease. Emory University researchers engineered a virus to make an intracellular antibody or "intrabody" against huntingtin, the protein whose mutant forms poison the brain cells of people with Huntington's.
Huntingtons Disease News From Medical News Today
Expanding on prior research performed at the University of Pennsylvania, Penn biologists have determined that faulty RNA, the blueprint that creates mutated, toxic proteins, contributes to a family of neurodegenerative disorders in humans.
| ||||||||||||||||||
| ||||||||||||||||||